Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Genet Med. Author manuscript; available in PMC 2017 August 15.
Published in final edited form as:
PMCID: PMC5557020

Recommendations for the Integration of Genomics into Clinical Practice

Sarah Bowdin, M.D.,2 Adel Gilbert, M.S.,2 Emma Bedoukian, M.S.,3 Christopher Carew, M.B.A.,2 Margaret P Adam, M.D.,4 John Belmont, M.D., Ph.D.,5 Barbara Bernhardt, M.S.,6 Leslie Biesecker, M.D.,7 Hans T. Bjornsson, M.D., Ph.D.,8 Miriam Blitzer, Ph.D.,9 Lisa C. A. D’Alessandro, M.D.,28 Matthew A. Deardorff, M.D., Ph.D.,3,27 Laurie Demmer, M.D.,10 Alison Elliott, Ph.D.,11 Gerald L. Feldman, M.D., Ph.D.,12 Ian A. Glass, M.B.Ch.B., M.D.,4 Gail Herman, M.D., Ph.D.,13 Lucia Hindorff, Ph.D.,7 Fuki Hisama, M.D.,26 Louanne Hudgins, M.D.,14 A. Micheil Innes, M.D.,15 Laird Jackson, M.D.,16 Gail Jarvik, M.D., Ph.D.,26 Raymond Kim, M.D., Ph.D.,1 Bruce Korf, M.D., Ph.D.,17 David H. Ledbetter, Ph.D.,18 Mindy Li, M.D.,19 Eriskay Liston, M.S.,1 Christian Marshall, Ph.D.,25 Livija Medne, M.S.,3 M. Stephen Meyn, M.D., Ph.D.,1,2 Nasim Monfared, M.Sc.,1 Cynthia Morton, Ph.D.,20 John J. Mulvihill, M.D.,21 Sharon E. Plon, M.D., Ph.D.,29 Heidi Rehm, Ph.D.,20 Amy Roberts, M.D.,22 Cheryl Shuman, M.S.,1,2 Nancy B. Spinner, Ph.D.,19 D. James Stavropoulos, Ph.D.,25 Kathleen Valverde, M.S.,23 Darrel J. Waggoner, M.D.,24 Alisha Wilkens, M.S.,3 Ronald D. Cohn, M.D.,1,2,* and Ian D. Krantz, M.D.2,27,*


The introduction of diagnostic clinical genome and exome sequencing (CGES) is changing the scope of practice for clinical geneticists. Many large institutions are making a significant investment in infrastructure and technology, allowing clinicians to access CGES especially as health care coverage begins to extend to clinically indicated genomic sequencing-based tests. Translating and realizing the comprehensive clinical benefits of genomic medicine remains a key challenge for the current and future care of patients. With the increasing application of CGES, it is necessary for geneticists and other health care providers to understand its benefits and limitations, in order to interpret the clinical relevance of genomic variants identified in the context of health and disease. Establishing new, collaborative working relationships with specialists across diverse disciplines (e.g., clinicians, laboratorians, bioinformaticians) will undoubtedly be key attributes of the future practice of clinical genetics and may serve as an example for other specialties in medicine. These new skills and relationships will also inform the development of the future model of clinical genetics training curricula.

To address the evolving role of the clinical geneticist in the rapidly changing climate of genomic medicine, two Clinical Genetics Think Tank meetings were held which brought together physicians, laboratorians, scientists, genetic counselors, trainees and patients with experience in clinical genetics, genetic diagnostics, and genetics education. This paper provides recommendations that will guide the integration of genomics into clinical practice.

Keywords: Genomics, clinical genetics, precision medicine, phenotyping, genetic counseling


Genetic diagnostics have evolved rapidly over the past six decades, changing the practice of clinical genetics and helping all medical specialties to achieve improved clinical outcomes. With techniques to see the correct complement of human chromosomes,1 genomic diagnostics through light microscopy was initiated. Three years later, the first genomic disorder, Down syndrome, was found to be associated with trisomy 21.2 The application of this “genomic” technology was limited for the next 30 years to diagnosing various germ line and somatic aneuploidies and translocations, with increasing resolution and the use of fluorescence in situ hybridization (FISH) beginning in the late 1980s.35 Comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) array-based methodologies allowed for the first genome-wide high-resolution analysis for small deletions and duplications,6 and replaced the G-banded karyotype as a first-tier diagnostic test.7 Ten years after this, the first applications of genome sequencing8 and exome sequencing912 to clinical medicine occurred and have since become widely used in diagnostics.13

With the expanded comprehensiveness of genetic testing, the interpretation of results has become more complex. Clinical genome and exome sequencing (CGES) promises to improve identification of the molecular determinants for many disease categories, but carries a degree of uncertainty given the large number of variants of uncertain significance (VUS) identified in any individual, as well as secondary findings unrelated to the primary indication for testing. Secondary findings are identified in 0.5–3.5% of individuals undergoing CGES,1418 but will increase as our knowledge about genetic determinants of disease advances. Indeed, as CGES evolves toward screening healthy populations, what we now consider secondary findings will become the primary findings, which will form the foundation for the practice of genomic precision medicine.19

The increasing complexity of CGES coupled with the broad scale application to a wide range of medical conditions requires a transformative approach to the ways we currently practice clinical genetics and medicine in general. New clinical models are needed to enable the integration of clinically relevant genomic information into specialized and routine healthcare.

Clinical Genetics Think Tank

The concept of a Clinical Genetics Think Tank (CGTT) evolved as it became evident that several clinical genetic centers in the United States and Canada were independently developing research and clinical programs to respond to demands for genomic services and were facing common challenges.20 The goals of the CGTT were to identify the major challenges to integrating CGES into clinical practice and to provide practical recommendations based on published evidence and professional experience.

Here, we outline the recommendations agreed upon by the CGTT, which are presented as a framework to influence policy discussions, provide guidance in the creation of new individualized care models incorporating family and patient preferences, and direction regarding how to integrate new genomic knowledge across organizations to ensure optimal management of patients undergoing CGES.

Five critical areas of focus in the clinical workflow to effectively integrate CGES were identified including; the pre-test process, pre-test education for patients and providers, phenotyping, sequence data interpretation and post-test patient care. For each area, we present challenges and recommendations followed by key questions, summarized in Table 1.

Table 1
Summary of the challenges discussed and recommendations made by the members of the Clinical Genetics Think Tank group.

PRE-TEST PROCESS: Patient selection and financial coverage issues for CGES

Many of the challenges of integrating CGES into clinical care are directly related to its huge diagnostic potential and its cost.20,21 As the cost/benefit ratio of CGES improves, some barriers to ordering this test are likely to fade.22 The diagnostic value will increase as genomic and phenotypic data are shared and interpreted, making it imperative that a robust pre-test process is developed to allow clinicians to utilize this test in the care of patients who are most likely to benefit.

Challenges and recommendations

Who should order CGES?

The American College of Medical Genetics and Genomics (ACMG) recommended that CGES should be accompanied by consultation with a genetics professional and adequate genetic counseling.23 Given the relatively small number of genetics professionals in the workforce and the projected increase in demand for CGES, the CGTT recommends that a clinician should be able to order CGES if he or she has a minimum knowledge base, with an opportunity to subsequently request additional expertise from a genetics professional (e.g., for pre-test evaluation or interpretation).

This minimum knowledge is defined by:

  1. Ability to perform a basic clinical genetics evaluation including family history, genetics-focused medical history and physical examination, and a critical summary of prior genetic evaluations.
  2. Ability to determine whether CGES is the test of choice for the specific clinical indication, considering other available tests (including genomic and non-genomic tests such as metabolic screening), the patient’s age, and cognitive ability.
  3. Ability to provide adequate pre-test counseling, including informed consent for primary and secondary findings.
  4. Ability to interpret the results of the CGES and provide adequate post-test counseling, or seek input for this step from a genetics professional.

What are the clinical indications to order CGES?

There are limited publications guiding the decision to order CGES.13,24,25 Figure 1 exhibits an algorithm following modification of a prior guideline25 and may require further modifications as evidence is published regarding the sensitivity of CGES in specific patient populations.

Figure 1
Algorithm to help identify patients most likely to benefit from clinical genome and exome sequencing (CGES)

The general principles guiding this algorithm are:

  1. When the patient’s phenotype is specific to a known genetic condition for which optimized genetic panel testing exists, the targeted gene panel should be given priority assuming it is more sensitive (e.g., Noonan spectrum disorders).
  2. Chromosome microarray analysis should be considered prior to CGES when the phenotype is not specific for a known genetic condition and when the family history does not indicate X-linked or autosomal recessive inheritance. This approach is suggested until the CNV calling sensitivity of CGES is equivalent to chromosome microarray platforms, and may become obsolete once genome sequencing (GS) is used as a platform, given the potential capability of GS to detect copy number variation at the same sensitivity as chromosome microarray.26,27
  3. CGES should be considered prior to chromosome microarray when there is parental consanguinity.28
  4. CGES should not be considered a mandatory next step when a targeted gene panel does not provide a diagnostic result. However, CGES in silico analysis may initially be focused on a specific subset of genes, and subsequently expanded to the full data set if the initial analysis is non-diagnostic (e.g., This approach may become ubiquitous as the cost of CGES falls and diagnostic laboratories streamline their workflows and maintain a “single platform” genetic test. Until then, clinicians may order CGES after a non-diagnostic gene panel if (a) there remains strong suspicion for a genetic cause and the gene panel previously ordered is outdated, or (b) the patient’s phenotype has evolved or is atypical for the negative panel, or (c) there is clinical urgency regarding the diagnosis and/or immediate clinical utility for family members who may be at risk.

Should there be an institutional gatekeeper?

Some institutions have established a gatekeeper role for access to CGES to promote appropriate patient selection.21 Boston Children’s Hospital BEST (Bringing Excellence to Selecting Tests) committee consists of members with sub-specialty expertise, who review all requests for CGES and provide educational feedback to the ordering clinician if a request is declined. Applications are initially reviewed by the content expert most closely related to the phenotype, who may approve the application or send it for full committee review. Given the potential benefits of education, quality and cost control associated with a gatekeeping role, institutions should give consideration to developing such a process, with diverse representation from institutional stakeholders. The precise model for each institution will vary, but may include the provision of guidelines (either institution-specific or peer-reviewed publications) that are a pre-requisite to accessing CGES, in addition to (or instead of) an individual or committee review of each application. The skill set required to review CGES applications is likely to be the same as that required to order and interpret the test, as outlined previously in the section entitled ‘Who should order CGES?’.

How should insurance approval for CGES be obtained?

Insurance companies and the Canadian Provincial Ministries of Health differ in their policies towards covering the cost of CGES. Several insurance providers have specific policies limiting and, in some cases denying, access based on the perception of CGES as an experimental or investigational technology.29 In the absence of access to CGES, less appropriate tests, often of equivalent or increased cost, may be ordered because those tests are covered by insurance.30

A recent study looking at insurance coverage for exome sequencing found extreme variability both among and within insurance providers which was heavily dependent on the indication for testing, and often involved large costs to the patients due to high deductibles and co-pays even when approved.22 A registry of next generation sequencing tests and reimbursement policies has been set up at UCSF’s Center for Translational and Policy Research on Personalized Medicine (, in order to track and inform decisions made by insurance representatives. Genetics professionals spend significant time writing letters of medical necessity to justify testing, and patients are referred to clinical genetics services for assistance in this process. Increased demand for this type of assistance would limit patient access to CGES since clinical genetics services are not available in the majority of healthcare settings. In the short term, sample letters of medical necessity should be made publically available in order to provide ordering clinicians the opportunity to adapt appropriately worded letters for their specific patient request. The letters should include references to regularly updated, peer-reviewed literature on clinical validity and utility, and patient satisfaction associated with CGES.

In the longer term, enhanced communication between professional bodies (advocating for CGES to be used on the basis of published evidence for improved diagnostic, management and patient satisfaction outcomes) and payers (articulating the industry’s pre-requisites to providing coverage for CGES) is necessary to increase accessibility to CGES. The American Society of Human Genetics (ASHG), ACMG and Canadian College of Medical Geneticists (CCMG) groups will need to play an active role and continue to work with payers to substantiate the clinical validity and utility of CGES. The periodic publication of practice guidelines by these professional bodies should be part of this effort.24


Multiple stakeholders require education about CGES, including physicians, genetic counselors, trainees, insurance and government stakeholders, laboratorians, and patients and their families. Education and informed consent have been thoroughly discussed elsewhere.3137 However, in order to facilitate broad implementation of CGES into clinical care, some areas require refinement in the context of increasingly advanced and complex genomic testing.

Challenges and Recommendations

Who requires education, and which are the key topics?


Patient education regarding CGES should be designed specifically for the target audience and extend beyond written information in the informed consent document. Several published articles and guidelines have outlined the topics considered essential to the informed consent process.38,39 The CGTT, primed by its patient and parental participants, concluded that it is most important to focus education on the types of results that are possible. A summary of the key patient education topics identified by the CGTT can be found in Table 2.

Table 2
Summary of key education topics for patients and families prior to ordering CGES


Provider education should be designed to enable assessment by clinicians of their ability and educational needs prior to ordering CGES. Topics should include: what a basic clinical genetics evaluation and family history entails, review of different types of genetic tests to allow for a critical summary of prior evaluations, overview of CGES (indications, strengths and limitations) to allow clinicians to determine whether this is the best test for the specific clinical indication, what is entailed in pre-test counseling, interpretation of results, post-test counseling, and when to seek support from a genetics professional.

Insurance and Government Stakeholders

Insurance providers and government bodies require an understanding of CGES in order to make informed decisions about test coverage and reimbursement levels. Key education topics are the clinical validity as it relates to the diagnosis and management of patients and their families as well as the utility of CGES for specific patient populations, which will be informed by data from research that is largely in its infancy.

How is education provided?

Clinician-patient interaction is key for adequate patient education; however patient educational materials should be provided as a supplement to the patient – clinician interaction.40 There are numerous online resources appropriate for patient education in CGES available at no cost (see Appendix 1). Their formats include video, interactive modules and expert-authored test descriptions designed to meet different educational requirements. Some have been translated into multiple languages to minimize disparities in access to CGES.

Clinical geneticists are already highly competent in many of the areas required to order and interpret CGES; however obtaining the specific skills required for clinical interpretation of CGES is a critical element of translating sequence into patient care. Development of specialty-specific educational opportunities should be promoted, such as the genomics case conferences sponsored by ACMG which focus on variant interpretation as it relates to CGES. Other short courses and continuing medical education (CME) modules are available across North America and worldwide, and details can be found on the websites of the professional societies including ASHG (, ACMG ( and the European Society of Human Genetics (ESHG) ( Clinician education methods may also include “on demand” learning, for example the electronic health record may contain prompts to training material when CGES is being electronically ordered.

PHENOTYPING: Collecting accurate, standardized phenotype data to assist test interpretation

The integration of clinical data, particularly a patient’s “phenotype”, is of central importance in determining what variants are most relevant during CGES interpretation. Accurate and consistent phenotype measures are needed to fully realize the utility of CGES; however, phenotype data are obtained by a wide range of medical specialties across many health care systems, and current methods for determining and recording phenotype information are not standardized. Recognition of the need to use standardized terms and measures for optimal phenotyping has stimulated worthy educational efforts to define phenotypic terms.4149 One powerful approach to standardize clinical data is the Human Phenotyping Ontology project (HPO) ( The HPO was designed to reflect normal clinical phenotyping processes, and is “a computational representation of a domain of knowledge (phenotype) based upon a controlled, standardized vocabulary for describing entities and the semantic relationships between them.”5052 Collecting clinical data for standardized phenotyping requires clinical databases to be either created or modified from pre-existing tools such as Phenotips53 ( This resource supports the use of HPO terms and allows for data entry functionality for PhenomeCentral, or PhenoDB (, permitting clinicians secure access to genotype-phenotype information and to collaborate on diagnoses. A full summary of online phenotype-genotype resources can be found in Table 3.

Table 3
Summary of Online Phenotype-Genotype resources

One approach to maximize the utility of standardized phenotypic data for analyzing CGES data would be to grant access to phenotypic data to the laboratory interpreting staff.

Challenges and Recommendations

How can consistent and uniform phenotype data be collected?

The phenotype may be focused for a specific clinical condition, suggesting a modular approach to phenotyping with the data content of individual modules defined for specific organ systems or diseases. In addition, a universal phenotypic data set could be established to assist in interpretation of as many primary and secondary findings on genomic testing as possible. Phenotypic measures developed for disease-specific research purposes (e.g., obesity) will help define which data should be captured for optimal CGES interpretation. Electronic health records (EHRs) need to be adapted to encompass universally consistent ontologic terms allowing for a common phenotyping language, and would play an essential role towards complete annotation of the variants in the human exome and genome from a clinical perspective.

Once phenotypic fields are delineated, it will be critical to get buy-in across organizations, nationally and internationally, to help disseminate robust information related to the significance of variants and mutations and their impact on phenotype, management, and clinical outcomes. A centralized and well-curated database containing both clinical and research genomic results linked to standardized phenotypic data would rapidly increase the accuracy of variant interpretation. Large-scale data collection will require broad scale efforts and institutional support, but the benefits in terms of standardized care, portability of information, and improved metrics to inform cost/benefit analyses would be potentially great.

How can dynamic phenotypes be captured in order to refine variant interpretation?

The ability to update phenotypic fields will be essential to understand the significance of variants identified on genomic testing across an individual’s lifespan. There is also a need to reassess variants of uncertain significance that may have been implicated in human disease in the interval since testing was performed. A post-CGES follow-up visit with a genetics professional would provide an opportunity to proactively manage patients in relation to their identified disease and risk variants, as well as update patients with new information related to the variants identified on initial testing. These visits would also provide an opportune time to update and establish comprehensive phenotypes on individuals and to institute the application of correct terminologies into the EHR. Establishment of automated care assistant models that could link genomic variants to populations at risk and provide recommended management options would streamline the process of reviewing an individual’s genome. Initial work in this domain is actively being pursued by research consortia supported through the NIH including the Electronic Medical Records and Genomics (eMERGE) Network (, the Clinical Sequencing Research Consortium (CSER) ( and the Implementing Genomics in Practice (IGNITE) consortium ( Recent work in applying such models to pharmacogenetic variants has shown the potential viability of such an approach.54,55

SEQUENCE DATA INTERPRETATION: Managing the integration of clinical and genomic information in order to generate a comprehensive clinical report

Much of the workflow (sequencing, alignment, variant calling) is standardized in diagnostic genomics laboratories. In comparison with gene panel testing, CGES interpretation requires closer collaboration between laboratorians and clinicians in order to reduce the number of genomic variants to be analyzed to a reasonable number. Fostering existing and establishing new relationships and processes to support these important interactions will ultimately ensure that CGES interpretation is accurate and efficient, and that the relevant information is communicated in a comprehensive clinical report.

Challenges and recommendations

How should laboratorians and clinicians interact to determine whether CGES is the appropriate test for a specific patient?

Determination of the correct diagnostic test for an individual patient should be the decision of the physician caring for the patient; however the diagnostic laboratory directors and genetic counselors should be available to provide feedback regarding the suitability of CGES relative to the clinical indication. Factors such as how well relevant genes are covered by CGES, as well as what types of variation are predominant in those genes are important for the ordering clinician to understand (e.g., triplet repeat expansions, copy number variants and other structural variants may not be well-covered by CGES).

How should variants be prioritized?

Identification and annotation of variants that are sufficiently relevant to the patient’s phenotype to be included in a focused clinical report are complex steps in the process of CGES interpretation.5457 Maintaining high stringency with respect to proof of pathogenicity at both gene and variant level will help to reduce the potentially severe consequences of misdiagnosis.58 The following recommendations aim to optimize this process:

  1. Where possible, laboratories should establish gene lists which relate to specific clinical indications for CGES, to help streamline initial variant calling and annotation. As population frequency resources are better integrated into pipelines reducing the number of variants to assess, the need to define gene lists in advance may be less relevant. Establishing gene lists does not imply that laboratories should limit CGES analysis to specific gene sets, however lists of genes known to be relevant to the patient’s indication for testing are helpful for prioritizing variants for deeper review, and for determining effective coverage. Community efforts to establish the level of evidence for gene-disease relationships, such as those undertaken by ClinGen ( will be critical in assessing which genes to review and how to report variants in those genes. These lists will require continual review and updating.
  2. Each laboratory should establish a comprehensive database to track their variant interpretations and evidence for classification, to enable this information to be shared and compared with other laboratories through publically available resources such as the ClinVar database.59

Should there be laboratory standards relating to depth of coverage and variant validation methods?

Variability in depth of coverage across the exome and genome leads to the possibility of gaps in sequencing and missing or uninterpretable data due to regions with high homology. The laboratory should make clear whether it will ensure completion or “fill-in” of any missing sequences or classes of variation that are relevant to the patient’s indication but technically difficult to access by CGES.55 Currently, laboratories are not routinely “filling in” gaps with Sanger sequencing. Diagnostic laboratories should establish mechanisms, by which clinicians can be informed of technical test limitations on a patient and indication-specific basis.

The common practice of confirming all pathogenic variants included in a clinical report by Sanger sequencing will become less warranted as validation efforts increase over time, and as laboratories ensure integrity of sample identity across complex genomic sequencing workflows.

Which variants should be included in the clinical report?

A critical issue is the decision regarding which variants are included in a formal clinical report.60 Results should be reported that definitively or likely explain the indication for CGES. If the laboratory decides to report variants in genes of uncertain significance (GUS) such as those with limited, no or conflicting evidence according to ClinGen’s framework but which represent strong candidates to explain the clinical findings, efforts should be made to refer to research-based evaluation for further clarification; it should be made explicit when evidence is lacking. Clinicians and CGES laboratory staff should be cognizant of the distinction between research and clinical care. Deposition of cases with candidate genes into Matchmaker Exchange is recommended ( For secondary findings, the threshold for inclusion in a clinical report should be more stringent than for the primary indication, and a minimal standard set of genes for inclusion of secondary variants (e.g., the ACMG recommendations)61 should be considered. The types of variants reported should be limited to likely pathogenic or pathogenic.54 In addition, reports should make it clear that complete detection and interpretation of all disease-associated variants is not possible.

POST-TEST PATIENT CARE: Return of primary and secondary findings and re-evaluation of CGES data

The post-test patient care phase begins once a CGES report has been returned to the ordering physician. In theory, this phase could last a lifetime, for the aspirational goal is to use DNA sequencing results to make a primary genomic diagnosis and to maintain health for a generation and even beyond. Additional factors that support the notion of a continuum of post-test patient care are the ever-changing methods of DNA analysis, the growing body of evidence and rules for interpreting the pathogenic potential of a variant, the anticipated inclusion of ‘omics’ methods, and animal models to further delineate clinical phenotypes. The initial appointment to discuss CGES results is likely to be the first of several post-test contacts between the patient and the medical team.

Challenges and Recommendations

How should primary and secondary results be returned?

The process of returning CGES results to the patient and other members of the medical team must be tailored to the diagnostic issue, the patient and family needs, the clinical setting, and the available workforce. The urgency and complexity of information to be returned to the patient should be balanced according to the patient’s stated wishes obtained during the pre-test consent process. Patients should have the choice of one or more results disclosure sessions to improve understanding and avoid fatigue. While we understand that it may be difficult to accommodate two sessions, and that in many circumstances one session only may be preferable for families, the feedback received from families and patient advocates should challenge the current health care model to allow for more than one session to discuss results of CGES. The first session addresses the principal diagnostic result. If the diagnostic or management issues relating to the primary diagnosis are outside the expertise of the ordering clinician, additional medical specialists may be invited to attend. Alternatively, the patient should be made aware of the need for obtaining specialist opinion(s), and the ordering clinician would complete a comprehensive referral including interpretation of the CGES results.

The second session should address secondary findings that are medically actionable, and be offered within a short time period after the first session if such findings exist. Pharmacogenomics variants would be addressed at this time, in consultation with a pharmacist or pharmacologist trained in interpreting pharmacogenetic data. This process is summarized in Figure 2.

Figure 2
Suggested post-clinical genome and exome sequencing patient-care algorithm.

Integration of CGES into electronic health records (EHR)

A significant number of institutions have implemented large-scale EHR systems that are uniformly aimed at improving patient care, safety and also address billing related issues. As CGES moves into daily clinical care, several providers of EHRs have begun developing modules that allow full integration of CGES results into the EHR of each patient. There are a number of aspects that require consideration for this to occur, which are beyond the scope of this manuscript. However, it is important to emphasize that detailed phenotypic analyses accompanied by primary, secondary and pharmacogenetic findings resulting from CGES should form part of the EHR in the most transparent way, in order to ensure patient safety and appropriate management.

Should genomic re-evaluation be offered?

Periodic re-evaluation of an individual’s genome with the aim of refining diagnostic interpretation is desirable, but requires significant time and financial commitments from laboratories, clinicians, and patients. Re-evaluation would apply both to those individuals whose CGES was diagnostic for their primary disorder and to those who did not receive a genomic diagnosis. A major issue concerning re-evaluation of CGES clinically is how to bill and be reimbursed for these services. The value of re-evaluation has been demonstrated in the research realm and several initiatives have demonstrated that automated re-querying of CGES data to capture novel disease associated variants is computationally possible. These initiatives are also able to compare variants amongst related cohorts to identify novel pathogenic variants associated with specific phenotypes. An excellent example of this is the Epilepsy Genetics Initiative (EGI) ( that is warehousing phenotype and genotype data (primarily exomes) contributed by clinicians and investigators and offering a re-analysis of the entire cohort every 6 months. While several diagnostic laboratories are offering free reanalysis within a specified time frame, guidelines need to be set for reimbursement for the diagnostic laboratories for these types of labor-intensive services. With 50–80% of clinical CGES tests having no identifiable definitive pathogenic variant on initial analysis, subsequent re-analysis as new information and pathogenic variants are identified will be critically important. Ideally at routine follow-up appointments, the family and personal health history would be updated, original sequencing results and interpretation reviewed, and DNA variant databases re-queried. If indicated, the physical examination would be repeated and follow up tests ordered. As functional testing becomes more accessible, VUS may be re-classified to allow diagnostic certainty. Supplementary ‘omics’ profiles, including metabolomics, transcriptomics, epigenomics and metagenomics, as well as animal models, already widely used in research may enable functional correlation with important genomic variants. These innovations should be the subject of early research on costs and effectiveness.


A number of papers have been written outlining issues related to implementation of genomic medicine into the clinic. Some focus on specific issues such as the evolving role of the medical geneticist,62 optimization and integration of genomic information in the EHR,63 research needs,64 ethical and legal aspects of returning results and distinguishing research from clinical care,65 and descriptions of institutional approaches to integration of genomic information into clinical care.20,66,67 Few have dealt with the practical aspects of implementation of genomic medicine into the clinic. The review of Biesecker and Green13 provided an overview of CGES, but did not focus on the obstacles to implementation. At a 2011 Colloquium of Genomic Medicine, sponsored by the US National Human Genome Research Institute (NHGRI), 20 groups of clinicians and investigators working on projects to implement genomic medicine summarized early findings.21 Some common challenges were seen: lack of consensus on the pathogenicity and clinical relevance of identified variants, reimbursement for genomic tests and interventions, the burden on clinicians and patients in managing the information generated from genomic testing, as well as infrastructural needs, such as open access knowledge base for cataloging variants and phenotypes. The Colloquium recognized that much of the work in clinical genomic medicine was being done in isolation and would benefit from active collaborative efforts and sharing of best practice, a catalyst for the CGTT workshops and this paper.

We hope that this outline will serve as the basis for continued interactions of various professional groups and will facilitate the establishment of collaborative infrastructures that are essential to implement best practices of clinical genomic medicine. It will only be through collaborative efforts and the application of consensus recommendations from different institutions and diverse populations (ethnically and racially, economically, prenatal, pediatric and adult for a wide spectrum of disease states and in healthy populations) that the robust data and metrics needed to evaluate the impact of genomic medicine on the health of individuals and populations will be able to be evaluated and best practice guidelines established for implementation of genomic medicine.

Supplementary Material

Appendix 1


Funding to cover attendance and accommodation for all participants at both meetings was provided by the Centre for Genetic Medicine, Hospital for Sick Children, Toronto, Canada and The Departments of Pediatrics and Pathology at The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

The Clinical Genetics Think Tank was funded by the Centre for Genetic Medicine, Hospital for Sick Children and the Departments of Pediatrics and Pathology at The Children’s Hospital of Philadelphia, with additional funding from the National Human Genome Research Institute (5UO1HG006546) (IDK, NBS). The authors acknowledge the parent and patient members of the CGTT – M. Hardy, B. Kovalski, H. Kovalski, D. Siciliano, J. Strautnieks, T. Stoppa and the support of Dr. Joe St. Geme and Dr. Bob Doms at the Children’s Hospital of Philadelphia. LGB was supported by the Intramural Research Program of the National Human Genome Research Institute.


Conflict of Interest

The authors of this manuscript declare no conflict of interest.

World Wide Web:

American College of Medical Genetics and Genomics (ACMG). Available at:

Matchmaker Exchange. Available at:

ClinGen. Available at:

US Food and Drug Administration. Available at:

Gene Dx Exome Slice. Available at:

UCSF Center for Translational and Policy Research on Personalized Medicine. Available at:

Human Phenotyping Ontology project (HPO). Available at:

PhenoTips. Available at:

PhenoDb. Available at:

Electronic Medical Records and Genomics (eMERGE) Network

Clinical Sequencing Research Consortium (CSER)

Implementing Genomics in Practice (IGNITE) consortium

Epilepsy Genetics Initiative (EGI)





1. Tjio JHLA. The chromosome number of man. Hereditas, Wiley On-Line Library. 1956;42:1–6. Available at:
2. Lejeune J, Gautier M, Turpin R. Study of somatic chromosomes from 9 mongoloid children. [French] Etude des chromosomes somatiques de neuf enfants mongoliens. Comptes rendus hebdomadaires des seances de l’Academie des sciences. 1959 Mar 16;248(11):1721–1722. [PubMed]
3. Pinkel D, Gray JW, Trask B, van den Engh G, Fuscoe J, van Dekken H. Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes. Cold Spring Harb Symp Quant Biol. 1986;51(Pt 1):151–157. [PubMed]
4. Kolvraa S, Koch J, Gregersen N, et al. Application of fluorescence in situ hybridization techniques in clinical genetics: use of two alphoid repeat probes detecting the centromeres of chromosomes 13 and 21 or chromosomes 14 and 22, respectively. Clin Genet. 1991 Apr;39(4):278–286. [PubMed]
5. Magenis RE, Maslen CL, Smith L, Allen L, Sakai LY. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics. 1991 Oct;11(2):346–351. [PubMed]
6. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998 Oct;20(2):207–211. [PubMed]
7. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010 May 14;86(5):749–764. [PubMed]
8. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008 Nov 6;456(7218):66–72. [PMC free article] [PubMed]
9. Ng SB, Buckingham KJ, Lee C, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010 Jan;42(1):30–35. [PMC free article] [PubMed]
10. Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19096–19101. [PubMed]
11. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009 Sep 10;461(7261):272–276. [PMC free article] [PubMed]
12. Maher B. Exome sequencing takes centre stage in cancer profiling. Nature. 2009 May 14;459(7244):146–147. [PubMed]
13. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014 Jun 19;370(25):2418–2425. [PubMed]
14. Johnston JJ, Rubinstein WS, Facio FM, et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet. 2012 Jul 13;91(1):97–108. [PubMed]
15. Dorschner MO, Amendola LM, Turner EH, et al. Actionable, pathogenic incidental findings in 1,000 participants’ exomes. Am J Hum Genet. 2013 Oct 3;93(4):631–640. [PubMed]
16. Tabor HK, Auer PL, Jamal SM, et al. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. Am J Hum Genet. 2014 Aug 7;95(2):183–193. [PubMed]
17. Amendola LM, Dorschner MO, Robertson PD, et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res. 2015 Mar;25(3):305–315. [PubMed]
18. Jurgens J, Ling H, Hetrick K, et al. Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics. Genet Med. 2015 Jan 8; [PMC free article] [PubMed]
19. Biesecker LG. Incidental variants are critical for genomics. Am J Hum Genet. 2013 May 2;92(5):648–651. [PubMed]
20. Bowdin S, Ray PN, Cohn RD, Meyn MS. The genome clinic: a multidisciplinary approach to assessing the opportunities and challenges of integrating genomic analysis into clinical care. Hum Mutat. 2014 May;35(5):513–519. [PubMed]
21. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013 Apr;15(4):258–267. [PMC free article] [PubMed]
22. Atwal PS, Brennan ML, Cox R, et al. Clinical whole-exome sequencing: are we there yet? Genet Med. 2014 Sep;16(9):717–719. [PubMed]
23. Points to consider in the clinical application of genomic sequencing. Genet Med. 2012 Aug;14(8):759–761. [PubMed]
24. Boycott K, Hartley T, Adam S, et al. The clinical application of genome-wide sequencing for monogenic diseases in Canada: Position Statement of the Canadian College of Medical Geneticists. J Med Genet. 2015 Jul;52(7):431–437. [PMC free article] [PubMed]
25. Shashi V, McConkie-Rosell A, Rosell B, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med. 2014 Feb;16(2):176–182. [PubMed]
26. Gilissen C, Hehir-Kwa JY, Thung DT, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014 Jul 17;511(7509):344–347. [PubMed]
27. Yuen RK, Thiruvahindrapuram B, Merico D, et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat Med. 2015 Feb;21(2):185–191. [PubMed]
28. Teeuw M, Waisfisz Q, Zwijnenburg PJ, et al. First steps in exploring prospective exome sequencing of consanguineous couples. Eur J Med Genet. 2014 Nov-Dec;57(11–12):613–616. [PubMed]
29. Deverka PA, Kaufman D, McGuire AL. Overcoming the reimbursement barriers for clinical sequencing. JAMA. 2014 Nov 12;312(18):1857–1858. [PMC free article] [PubMed]
30. Chakradhar S. Insurance companies are slow to cover next-generation sequencing. Nat Med. 2015 Mar;21(3):204–205. [PubMed]
31. Vrijenhoek T, Kraaijeveld K, Elferink M, et al. Next-generation sequencing-based genome diagnostics across clinical genetics centers: implementation choices and their effects. Eur J Hum Genet. 2015 Jan 28; [PMC free article] [PubMed]
32. Scollon S, Bergstrom K, Kerstein RA, et al. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014;6(9):69. [PMC free article] [PubMed]
33. Henderson GE, Wolf SM, Kuczynski KJ, et al. The challenge of informed consent and return of results in translational genomics: empirical analysis and recommendations. J Law Med Ethics. 2014 Fall;42(3):344–355. [PMC free article] [PubMed]
34. Bergner AL, Bollinger J, Raraigh KS, et al. Informed consent for exome sequencing research in families with genetic disease: the emerging issue of incidental findings. Am J Med Genet A. 2014 Nov;164A(11):2745–2752. [PMC free article] [PubMed]
35. Appelbaum PS, Parens E, Waldman CR, et al. Models of consent to return of incidental findings in genomic research. Hastings Cent Rep. 2014 Jul-Aug;44(4):22–32. [PMC free article] [PubMed]
36. Points to consider for informed consent for genome/exome sequencing. Genet Med. 2013 Sep;15(9):748–749. [PubMed]
37. Levenseller BL, Soucier DJ, Miller VA, Harris D, Conway L, Bernhardt BA. Stakeholders’ opinions on the implementation of pediatric whole exome sequencing: implications for informed consent. J Genet Couns. 2014 Aug;23(4):552–565. [PMC free article] [PubMed]
38. Ayuso C, Millan JM, Mancheno M, Dal-Re R. Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and process. Eur J Hum Genet. 2013 Oct;21(10):1054–1059. [PMC free article] [PubMed]
39. Tabor HK, Stock J, Brazg T, et al. Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. Am J Med Genet A. 2012 Jun;158A(6):1310–1319. [PMC free article] [PubMed]
40. Core competencies in genetics for heath professionals. NCHPEG (National Coalition for Health Professional Education in Genetics); 2007.
41. Hennekam RC, Allanson JE, Biesecker LG, Carey JC, Opitz JM, Vilain E. Elements of morphology: standard terminology for the external genitalia. Am J Med Genet A. 2013 Jun;161A(6):1238–1263. [PMC free article] [PubMed]
42. Carey JC. Editor’s forward to special articles: elements of morphology. Am J Med Genet A. 2013 Nov;161A(11):2710. [PubMed]
43. Biesecker LG, Carey JC. Implementing the elements of morphology in the American Journal of Medical Genetics. Am J Med Genet A. 2011 May;155A(5):969–971. [PubMed]
44. Hennekam RC, Cormier-Daire V, Hall JG, Mehes K, Patton M, Stevenson RE. Elements of morphology: standard terminology for the nose and philtrum. Am J Med Genet A. 2009 Jan;149A(1):61–76. [PubMed]
45. Hunter A, Frias JL, Gillessen-Kaesbach G, Hughes H, Jones KL, Wilson L. Elements of morphology: standard terminology for the ear. Am J Med Genet A. 2009 Jan;149A(1):40–60. [PubMed]
46. Allanson JE, Cunniff C, Hoyme HE, McGaughran J, Muenke M, Neri G. Elements of morphology: standard terminology for the head and face. Am J Med Genet A. 2009 Jan;149A(1):6–28. [PMC free article] [PubMed]
47. Allanson JE, Biesecker LG, Carey JC, Hennekam RC. Elements of morphology: introduction. Am J Med Genet A. 2009 Jan;149A(1):2–5. [PMC free article] [PubMed]
48. Biesecker LG, Aase JM, Clericuzio C, Gurrieri F, Temple IK, Toriello H. Elements of morphology: standard terminology for the hands and feet. Am J Med Genet A. 2009 Jan;149A(1):93–127. [PMC free article] [PubMed]
49. Carey JC, Cohen MM, Jr, Curry CJ, Devriendt K, Holmes LB, Verloes A. Elements of morphology: standard terminology for the lips, mouth, and oral region. Am J Med Genet A. 2009 Jan;149A(1):77–92. [PubMed]
50. Robinson PN, Mundlos S. The human phenotype ontology. Clin Genet. 2010 Jun;77(6):525–534. [PubMed]
51. Kohler S, Doelken SC, Mungall CJ, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 2014 Jan;42:D966–974. Database issue. [PMC free article] [PubMed]
52. Robinson PN, Kohler S, Bauer S, Seelow D, Horn D, Mundlos S. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet. 2008 Nov;83(5):610–615. [PubMed]
53. Girdea M, Dumitriu S, Fiume M, et al. PhenoTips: patient phenotyping software for clinical and research use. Hum Mutat. 2013 Aug;34(8):1057–1065. [PubMed]
54. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405–424. [PMC free article] [PubMed]
55. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013 Sep;15(9):733–747. [PMC free article] [PubMed]
56. Gargis AS, Kalman L, Berry MW, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol. 2012 Nov;30(11):1033–1036. [PMC free article] [PubMed]
57. Duzkale H, Shen J, McLaughlin H, et al. A systematic approach to assessing the clinical significance of genetic variants. Clin Genet. 2013 Nov;84(5):453–463. [PMC free article] [PubMed]
58. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014 Apr 24;508(7497):469–476. [PMC free article] [PubMed]
59. Rehm HL, Berg JS, Brooks LD, et al. ClinGen–the Clinical Genome Resource. N Engl J Med. 2015 Jun 4;372(23):2235–2242. [PMC free article] [PubMed]
60. Jarvik GP, Amendola LM, Berg JS, et al. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet. 2014 Jun 5;94(6):818–826. [PubMed]
61. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med. 2015 Jan;17(1):68–69. [PubMed]
62. Korf BR, Ledbetter D, Murray MF. Report of the Banbury Summit Meeting on the evolving role of the medical geneticist, February 12-14, 2006. Genet Med. 2008 Jul;10(7):502–507. [PubMed]
63. Kullo IJ, Jarvik GP, Manolio TA, Williams MS, Roden DM. Leveraging the electronic health record to implement genomic medicine. Genet Med. 2013 Apr;15(4):270–271. [PMC free article] [PubMed]
64. Manolio TA, Green ED. Leading the way to genomic medicine. Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):1–7. [PubMed]
65. Burke W, Evans BJ, Jarvik GP. Return of results: ethical and legal distinctions between research and clinical care. Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):105–111. [PMC free article] [PubMed]
66. Jacob HJ, Abrams K, Bick DP, et al. Genomics in clinical practice: lessons from the front lines. Sci Transl Med. 2013 Jul 17;5(194):194cm195. [PubMed]
67. Vassy JL, Lautenbach DM, McLaughlin HM, et al. The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials. 2014;15:85. [PMC free article] [PubMed]